| Literature DB >> 27808277 |
Dorota Kamińska1, Katarzyna Kościelska-Kasprzak1, Paweł Chudoba2, Agnieszka Hałoń3, Oktawia Mazanowska4, Agnieszka Gomółkiewicz5, Piotr Dzięgiel5, Dominika Drulis-Fajdasz1, Marta Myszka1, Agnieszka Lepiesza2, Wojciech Polak6, Maria Boratyńska1, Marian Klinger1.
Abstract
Kidney surface cooling was used during implantation to assess the effect of warm ischemia elimination on allograft function, histological changes and immune-related gene expression. 23 recipients were randomly assigned to a group operated on with kidney surface cooling during implantation (ice bag technique, IBT group), and the other 23 recipients receiving the contralateral kidney from the same donor were operated on with a standard technique. Three consecutive kidney core biopsies were obtained during the transplantation procedure: after organ recovery, after cold ischemia and after reperfusion. Gene expression levels were determined using low-density arrays (Format 32, TaqMan). The IBT group showed a significantly lower rate of detrimental events (delayed graft function and/or acute rejection, p = 0.015) as well as higher glomerular filtration rate on day 14 (p = 0.026). A greater decrease of MMP9 and LCN2 gene expression was seen in the IBT group during total ischemia (p = 0.003 and p = 0.018). Elimination of second warm ischemia reduced the number of detrimental events after kidney transplantation, and thus had influence on the short-term but not long-term allograft function. Surface cooling of the kidney during vascular anastomosis may reduce some detrimental effects of immune activation resulting from both brain death and ischemia-reperfusion injury.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27808277 PMCID: PMC5093711 DOI: 10.1038/srep36118
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Distribution of detrimental posttransplant events between studied groups.
| STANDARD | IBT | p | |
|---|---|---|---|
| 26.6 ± 9.8 | 22.4 ± 11.8 | 0.82 | |
| 8 (35%) | 5 (22%) | 0.51 | |
| 10 (43%) | 4 (17%) | 0.11 | |
| 2 (8%) | 2 (8%) | 1.00 | |
| 2/4/2 | 1/0/1 | 0.074 | |
| 14 (61%) | 6 (26%) |
*DGF – delayed graft function, BPAR – biopsy-proven acute rejection in 1st year, AMR – antibody-mediated rejection, assessment according to Banff’05 criteria.
Kidney allograft function according to type of transplant procedure (ST vs IBT, paired analysis).
| STANDARD | IBT | p | |||
|---|---|---|---|---|---|
| mean ± SD | median | mean ± SD | median | ||
| GFR 7 days | 24 ± 18 | 25 | 38 ± 22 | 38 | 0.065 |
| GFR 14 days | 31 ± 18 | 34 | 43 ± 19 | 43 | |
| GFR 1 month | 40 ± 19 | 36 | 45 ± 18 | 50 | 0.10 |
| GFR 3 months | 47 ± 15 | 45 | 44 ± 21 | 38 | 0.63 |
| GFR 6 months | 46 ± 12 | 42 | 47 ± 14 | 44 | 0.92 |
| GFR 12 months | 49 ± 18 | 45 | 49 ± 17 | 46 | 0.59 |
| GFR 18 months | 52 ± 12 | 48 | 50 ± 15 | 50 | 1.00 |
| GFR 24 months | 48 ± 16 | 45 | 52 ± 19 | 50 | 0.50 |
| GFR 60 months | 47 ± 19 | 50 | 49 ± 21 | 49 | 0.55 |
Histological evaluation of biopsy 1 with Remuzzi score (p = ns).
| ST | IBT | |
|---|---|---|
| Mean [values] | ||
| 0.7 [0–1] | 0.6 [0–1] | |
| 0.7 [0–1] | 0.8 [0–1] | |
| 0.2 [0–1] | 0.3 [0–1] | |
| 0.8 [0–2] | 0.7 [0–1] | |
| (Mean ± SD) | ||
| 2.6 ± 1.6 | 2.4 ± 1.5 | |
*Remuzzi score ST vs IBT p = ns.
Histopathological assessment of biopsies – tubular compartment (TOV index); T – tubular necrosis, O – edema of epithelial cells, V – vacuolization of epithelial cells.
| TOV | Biopsy 1 (ST/IBT) | Biopsy 2 (ST/IBT) | Biopsy 3A ST | Biopsy 3B IBT | p 3A vs 3B | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 0 | 1 | 2 | 0 | 1 | 2 | 0 | 1 | 2 | ns | |
| 22/22 | 1/1 | 0/0 | 9/7 | 11/9 | 5/5 | 8 | 23 | 15 | 12 | 23 | 11 | ns | |
| 17/21 | 4/2 | 1/1 | 7/11 | 10/14 | 1/3 | 13 | 26 | 7 | 16 | 25 | 5 | ns | |
| 18/16 | 3/5 | 1/3 | 7/6 | 11/12 | 6/4 | 8 | 26 | 12 | 8 | 26 | 12 | ns | |
*TOV index: 0 – no changes, 1 – low grade, 2 – mild, 3 – high grade (high grade was absent in all biopsies).
Immunohistochemical analysis of kidney tissue.
| Biopsy 1 (ST/IBT) | Biopsy 2 (ST/IBT) | Biopsy 3A ST | Biopsy 3B IBT | p 3A vs 3B | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 0 | 1 | 2 | 0 | 1 | 2 | 0 | 1 | 2 | ||
| alpha-SMA g | 13/19 | 0/0 | 2/3 | 14/12 | 2/0 | 1/0 | 6 | 6 | 0 | 7 | 7 | 1 | ns |
| alpha-SMA t | 5/7 | 10/9 | 4/3 | 3/2 | 7/7 | 10/9 | 1 | 4 | 14 | 1 | 3 | 13 | ns |
| p53 g | 16/13 | 1/2 | 0/0 | 12/16 | 0/1 | 1/0 | 10 | 2 | 0 | 13 | 2 | 0 | ns |
| p53 t | 5/5 | 12/10 | 3/2 | 1/2 | 10/13 | 6/5 | 1 | 8 | 9 | 2 | 9 | 6 | ns |
| Bcl-2 g | 4/6 | 7/9 | 2/3 | 6/4 | 8/5 | 3/2 | 3 | 8 | 1 | 5 | 7 | 3 | ns |
| Bcl-2 t | 0/0 | 2/0 | 20/15 | 0/0 | 2/2 | 12/11 | 0 | 4 | 13 | 0 | 2 | 16 | ns |
*IRS index: 0 – no changes, 1 – low grade, 2 – mild, 3 – high grade, t – tubules, g – glomeruli.
Figure 1Gene expression presented as ΔΔCt (dot-median, line-interquartile range).
Data presented for each of the three biopsies (B1-light gray, B2-dark grey, B3-black).
Figure 2The change in MMP9 and LCN2 gene expression levels over ischemia time in matched pairs of the kidneys from the same donor as observed in IBT (grey box) vs ST group (white box).
Data presented as median (horizontal line), interquartile range (box), and values range (vertical line).
Donor and recipient characteristics in examined groups (standard and IBT).
| STANDARD | IBT | p | |
|---|---|---|---|
| Donor gender | 10F/13M | ||
| Donor age (years, mean ± SD) | 48 ± 12 | ||
| Donor last creatinine (mg/dL) | 1.13 ± 0.46 | ||
| Donor cause of death | 16 cerebrovascular accident, 7 other | ||
| CIT (hours, mean ± SD) | 28.6 ± 7.4 | 27.4 ± 7.5 | ns |
| WIT (minutes, mean ± SD) | 23.6 ± 8.1 | 0 | p < 0.0001 |
| Recipient gender | 10F/13M | 7F/16M | ns |
| Recipient age (years, mean ± SD) | 50 ± 13 | 52 ± 10 | ns |
| Primary kidney disease: | |||
| 10 | 10 | ||
| 4 | 6 | ||
| 1 | 3 | ||
| 6 | 1 | ||
| 2 | 3 | ||
| Time of dialysis before transplantation (months, mean ± SD) | 27.5 ± 19.8 | 28.0 ± 18.1 | ns |
| Dialysis method (HD/PD) | 19/4 | 20/3 | ns |
| HLA mismatches (mean ± SD) | 4.1 ± 1.1 | 3.9 ± 1.0 | ns |
| Max. PRA >20% | 4 | 2 | ns |
| Last PRA >20% | 2 | 0 | ns |
| Second transplant | 4 | 1 | ns |
| Immunosuppression | |||
| 16 | 13 | ||
| 7 | 9 | ||
| 1 | |||
| 1 | 2 | ||
*HD-hemodialysis, PD-peritoneal dialysis, PRA-panel reactive antibodies, TAC-tacrolimus, MPA- mycophenolate mofetil/sodium, CsA-cyclosporine A, mTORI- mTOR inhibitors.